Skip to content

Author

Jacques Cadranel

We have 2 of 41 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.

Small-molecule oral Janus kinase (JAK) inhibitors are increasingly used for treatment of digestive and rheumatic inflammatory diseases or haematological disorders. Based on limited data, the risk of tuberculosis (TB) has been reported but considered lower compared with that observed with TNF-α inhibitors a finding we p...

T. Maitre, K. Bihan, Nicolas Veziris et al. · 0 citations
Open access Aug 2026

Prevalence and outcomes of pleuroparenchymal fibroelastosis in patients with non-tuberculous mycobacterial pulmonary disease: a French retrospective cohort study

PPFE is frequently observed among patients with NTM-PD, and seems to be associated with a lower BMI and the 5-year mortality, supporting its systematic screening in this population.

Maïwenn Poidevin-Belkadi, Samia Boussouar, N. Véziris et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.